RxDoctor Payments Data

Thomas Hubbard, MD

Family Medicine · Ashland, VANPI 1588633267

Payments from drug & device makers

$8,925in general payments, 2019–2025

Across 526 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Amgen$941
  • Novo Nordisk$735
  • Lilly USA, LLC$597
  • Esperion Therapeutics, Inc.$507
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$8,67597%
  • Gifts$2503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,925 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$202,555
Medicare patients
402
Services billed
2,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol127$159,985
OzempicSemaglutide58$73,756
JanuviaSitagliptin Phosphate25$38,204
EliquisApixaban23$27,780
NexlizetBempedoic Acid/Ezetimibe22$24,943
NexletolBempedoic Acid24$23,341
Ezetimibe450$12,936
Breo ElliptaFluticasone/Vilanterol13$8,804
Rosuvastatin Calcium546$6,688
Atorvastatin Calcium634$5,567
Potassium Chloride126$3,775
Losartan Potassium434$3,589
Amlodipine Besylate714$3,557
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm16$3,463
Lisinopril436$2,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,933$159,985127 claims
Novo NordiskOzempic$735$73,75658 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$507$48,28346 claims
MerckJanuvia$38$38,20425 claims
PfizerEliquis$397$27,78023 claims
GSKBreo Ellipta$240$8,80413 claims
AbbVieSynthroid$1,347$1,59337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Ashland

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →